Advertisement

Topics

Cavion Appoints Papapetropoulos, M.D., Ph.D. as EVP, R&D and CMO

16:03 EDT 16 Aug 2017 | Virginia Biotechnology

Cavion, Inc., a clinical stage biopharmaceutical company, names Dr. Spyridon "Spyros" Papapetropoulos as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Papapetropoulos will lead Cavion’s research and development organization to advance therapies based on the company’s T-type calcium channel (Cav3) platform.

“Spyros joins the Cavion team at an exciting time. He is an experienced leader with a passion for conducting innovative trials that deliver new treatment options to patients with neurological diseases with limited treatment options,” said Cavion CEO and President Andrew Krouse. He added, “Spyros will help extend Cavion’s presence in the Boston/Cambridge area.”

Dr. Papapetropoulos noted, “Cavion’s selective Cav3 modulating platform, which includes best-in-class clinical stage compounds, is expected to restore rhythmic neuronal firing in brain regions associated with a variety of chronic neurological diseases.” He added, “I look forward to working closely with Cavion’s team to apply innovative but empathetic approaches to achieving clinical breakthroughs. Our end goal is to bring safe, effective and accessible treatments to people with chronic neurological diseases, quickly and efficiently.”

Dr. Papapetropoulos has extensive academic, biopharmaceutical and digital health experience, most recently serving as Vice President, Global Specialty Development, Neurodegenerative Diseases, Movement Disorders and Clinical Trial Innovation for Teva Pharmaceutical Industries Ltd. Prior to Teva, he managed neuroscience research and medical affairs programs at Pfizer Inc., Allergan Inc., and Biogen Idec Inc. Dr. Papapetropoulos has overseen a wide spectrum of pharmaceutical development programs from regulatory filing to new product launch. He holds appointments as consultant with Massachusetts General Hospital and voluntary Professor of Neurology with the University of Miami, Miller School of Medicine.

Original Article: Cavion Appoints Papapetropoulos, M.D., Ph.D. as EVP, R&D and CMO

NEXT ARTICLE

More From BioPortfolio on "Cavion Appoints Papapetropoulos, M.D., Ph.D. as EVP, R&D and CMO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...